Gilpin Wealth Management’s Collegium Pharmaceutical COLL Stock Holding History

Gilpin Wealth Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$241	Buy	11 +6	+120%	+$175	﹤0.01%	1064
2026 Q2	$181	Hold	5	–	–	﹤0.01%	939
2026 Q1	$166	Hold	5	–	–	﹤0.01%	892
2025 Q4	$232	Buy	+5	New	+$209	﹤0.01%	619

Other funds holding COLL

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Gilpin Wealth Management's COLL Position: Q3 2026 in Review

Gilpin Wealth Management increased its Collegium Pharmaceutical (COLL) stake by 120% in Q3 2026, buying an estimated $175 and bringing the position to 11 shares worth $241. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

Gilpin Wealth Management first reported a position in COLL in Q4 2025 and has held it in 4 quarters since. 7 funds tracked by Wall St. Rank hold COLL as of Q3 2026.

Gilpin Wealth Management held 11 shares of Collegium Pharmaceutical worth $241 as of Q3 2026.
Gilpin Wealth Management bought 6 Collegium Pharmaceutical shares in Q3 2026, an estimated $175.
Collegium Pharmaceutical made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1064 holding.
Gilpin Wealth Management first reported a position in Collegium Pharmaceutical in Q4 2025 and has held it in 4 quarters since.
7 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.